About: Diagnosis of severe respiratory infections in immunocompromised patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnosis of severe respiratory infections in immunocompromised patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Diagnosis of severe respiratory infections in immunocompromised patients
Creator	Rello, Jordi Azoulay, Elie Povoa, Pedro Lemiale, Virginie Mehta, Sangeeta Mokart, Djamel Mirouse, Adrien Bauer, Philippe Loeches, Ignacio Metaxa, Victoria Montero, José Puxty, Kathryn Russell, Lene Schellongowski, Peter Van De Louw, Andry
source	PMC
abstract	An increasing number of critically ill patients are immunocompromised. Acute hypoxemic respiratory failure (ARF), chiefly due to pulmonary infection, is the leading reason for ICU admission. Identifying the cause of ARF increases the chances of survival, but may be extremely challenging, as the underlying disease, treatments, and infection combine to create complex clinical pictures. In addition, there may be more than one infectious agent, and the pulmonary manifestations may be related to both infectious and non-infectious insults. Clinically or microbiologically documented bacterial pneumonia accounts for one-third of cases of ARF in immunocompromised patients. Early antibiotic therapy is recommended but decreases the chances of identifying the causative organism(s) to about 50%. Viruses are the second most common cause of severe respiratory infections. Positive tests for a virus in respiratory samples do not necessarily indicate a role for the virus in the current acute illness. Invasive fungal infections (Aspergillus, Mucorales, and Pneumocystis jirovecii) account for about 15% of severe respiratory infections, whereas parasites rarely cause severe acute infections in immunocompromised patients. This review focuses on the diagnosis of severe respiratory infections in immunocompromised patients. Special attention is given to newly validated diagnostic tests designed to be used on non-invasive samples or bronchoalveolar lavage fluid and capable of increasing the likelihood of an early etiological diagnosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-019-05906-5) contains supplementary material, which is available to authorized users.
has issue date	2020-02-07(xsd:dateTime)
bibo:doi	10.1007/s00134-019-05906-5
bibo:pmid	32034433
has license	no-cc
sha1sum (hex)	49a3a223b6b40c1bf6d9d83db3b37b93f1621bec
schema:url	https://doi.org/10.1007/s00134-019-05906-5
resource representing a document's title	Diagnosis of severe respiratory infections in immunocompromised patients
has PubMed Central identifier	PMC7080052
has PubMed identifier	32034433
schema:publication	Intensive Care Med
resource representing a document's body	covid:49a3a223b6b40c1bf6d9d83db3b37b93f1621bec#body_text
is schema:about of	named entity 'likelihood' named entity 'designed' named entity 'severe' named entity 'respiratory infections' named entity 'immunocompromised' named entity 'infections' named entity 'Special' named entity 'complex' named entity 'Pneumocystis jirovecii' named entity 'identifying' named entity 'bacterial pneumonia' named entity 'non-infectious' named entity 'virus' named entity 'non-invasive' named entity 'pulmonary infection' named entity 'respiratory infections' named entity 'infectious agent' named entity 'Pneumocystis jirovecii' named entity 'immunocompromised patients' named entity 'number' named entity 'incidence rate' named entity 'resistance genes' named entity 'Bacterial pneumonia' named entity 'neutropenia' named entity 'cutaneous disease' named entity 'pathogens' named entity 'infection' named entity 'pneumonia' named entity 'immunosuppression' named entity 'alveolar' named entity 'pleural effusion' named entity 'cardiomegaly' named entity 'lungs' named entity 'CMV' named entity 'HSCT' named entity 'immunocompromised patients' named entity 'seropositive' named entity 'interstitial pneumonia' named entity 'severe infections' named entity 'Chest imaging' named entity 'organism' named entity 'hematology' named entity 'ARF' named entity 'strongyloidiasis' named entity 'varicella-zoster virus' named entity 'tenosynovitis' named entity 'pneumonia' named entity 'mnemonic' named entity 'living organisms' named entity 'respiratory distress' named entity 'hemorrhage' named entity 'non-invasive' named entity 'biologic therapies' named entity 'RSV' named entity 'Mycobacterial' named entity 'HSCT' named entity 'fatigue' named entity 'neutropenic' named entity 'RSV infection' named entity 'ground-glass opacities' named entity 'cavitation' named entity 'immunocompromised patients' named entity 'DNA hybridization' named entity 'TMP/SMX' named entity 'asymptomatic carriers' named entity 'critically ill patients' named entity 'strongyloidiasis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software